Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication March 24, 2017
- Accepted for publication May 31, 2017
- Published online January 2, 2018.
Article Versions
- previous version (June 21, 2017 - 05:23).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Joanne E. Mortimer1,
- James R. Bading1,
- Jinha M. Park2,
- Paul H. Frankel3,
- Mary I. Carroll1,
- Tri T. Tran2,
- Erasmus K. Poku4,
- Russell C. Rockne3,
- Andrew A. Raubitschek4,
- John E. Shively5 and
- David M. Colcher4
- 1Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California
- 2Department of Radiology, City of Hope, Duarte, California
- 3Department of Information Sciences, City of Hope, Duarte, California
- 4Department of Cancer Immunotherapy and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California; and
- 5Department of Immunology, Beckman Research Institute of the City of Hope, Duarte, California
- For correspondence or reprints contact: Joanne Mortimer, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Rd., Duarte, CA 91010. E-mail: jmortimer{at}coh.org
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients
- Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study
- Towards integration of 64Cu-DOTA-Trasztusumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2+ breast cancer
- Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTA
- Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies
- PET Imaging of Receptor Tyrosine Kinases in Cancer